{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020447","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.997543+00:00","generated_at":"2026-06-02T22:17:06.043534+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR","bullets":["ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.","Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.","Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.","LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.","Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020447","json":"https://secwatch.observer/filing/0001628280-24-020447.json","markdown":"https://secwatch.observer/filing/0001628280-24-020447.md","text":"https://secwatch.observer/filing/0001628280-24-020447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/adc-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:17:06.043534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"756c6260785459d16af2001b76aa894944648a2a","claim":"ADC Therapeutics SA reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 6, 2024, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024020447/0001628280-24-020447-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}